TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07036510: Early Feasibility Study to Evaluate the Safety and Efficacy of a New Timolol Sustained-Release Intraocular Implant (TimoD) in Participants With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Undergoing Cataract S

Sponsor: EyeD Pharma · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 42 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07036510 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07036510 Rescue Dossier →